Enrollment in U.S. Pilot Study Evaluating Bioelectronic Device for Treatment of Rheumatoid Arthritis Completed
10/17/18: The primary purpose of this multi-center, randomized study is to evaluate safety and tolerability of SetPoint’s proprietary device, which is surgically placed on the vagus nerve. The study includes 14 subjects who had failed or were intolerant to multiple, mechanistically different, biologic therapies. Initial feedback from neurosurgeons performing the implantation has been positive. The company anticipates data readout in the first quarter of 2019.
SetPoint Medical Presents Positive Data from its Clinical Study of Bioelectronic Medicine for Treatment of Crohn’s Disease
6/11/18: This open-label study was conducted at five European centers and included 16 patients with moderate to severe Crohn’s disease with inadequate responses to tumor necrosis factor (TNF) antagonist drugs and other non-TNF targeted biologic agents. All patients were implanted with a vagus nerve stimulating device to deliver digital doses of electricity designed to activate the cholinergic anti-inflammatory reflex to produce a systemic immunorestorative effect.
SetPoint Medical Announces U.S. Pilot Trial to Evaluate First Bioelectronic Device to Treat Rheumatoid Arthritis
3/26/18: Trial assesses proprietary new device that delivers doses of electricity to treat rheumatoid arthritis; Builds on first-in-human data.
SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, announced today...